Briefing

Featured article

Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa

Also in this section

News in Numbers

Latest News

Latest Deals

Project Updates

Trends & Insight

04/15/2026 08:34:05
  • Home | Digital twins become the new battleground for CDMOs
  • Editor's letter
  • Contents
  • Cencora
  • LATAM Cargo Company Insight
  • LATAM Cargo
  • Phillips Medisize Company Insight
  • Phillips Medisize
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Air France KLM Martinair Cargo
  • LAST Technology
  • Steris
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Syngene Company Insight
  • In Depth
  • Digital twins become the new battleground for CDMOs
  • How physical AI is rewiring pharma manufacturing
  • UAE stem cell specialist CellSave Arabia targets growth in regenerative medicine
  • Drugmakers fortify supply chains ahead of obesity pill boom
  • China’s biotech surge upends the global CDMO model
  • Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition
  • Autologous versus allogeneic: how cell therapy development is changing in oncology
  • 2025 dominated in ALS research
  • Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
  • Datwyler Company Insight
  • Datwyler
  • Chemspec Europe Company Insight
  • Chemspec Europe
  • Events
  • Next issue
04/16/2026 00:00:00